Icatibant Stada

Icatibant, the active ingredient in Icatibant Stada, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1 inhibitor deficiency.

GNH USA supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to target bradykinin‑mediated swelling in hereditary angioedema and related conditions.

- Acute hereditary angioedema attacks: provides rapid relief of swelling and pain. - Hereditary angioedema type I and II: reduces frequency and severity of episodes. - C1‑inhibitor deficiency‑related angioedema: controls sudden edema events.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic response.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient increase in local tissue volume. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate head pain. - Dizziness: transient feeling of light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Airway angioedema: swelling that may compromise breathing. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: low platelet count. - Necrotic skin lesions: rare severe skin damage at injection site. - Systemic hypersensitivity: widespread rash or urticaria.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; use only if benefits outweigh risks. - Breastfeeding: caution advised as drug may pass into milk. - Renal impairment: monitor patients with reduced kidney function. - Concomitant ACE inhibitors or neprilysin inhibitors: may increase bradykinin‑related effects. - Known hypersensitivity: discontinue if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that affect bradykinin pathways or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and risk of angioedema. - Neprilysin inhibitors: additive effect on bradykinin accumulation. - Estrogen‑containing contraceptives: may exacerbate hereditary angioedema.

Moderate Interactions (Monitor Closely): - Diuretics: may alter fluid balance and affect swelling response. - Beta‑blockers: could mask symptoms of hypotension. - Other B2 receptor antagonists: potential additive pharmacologic effect.